Carter Todd Alfred 4

What Happened

• Carter Todd Alfred, Chief Scientific Officer of Voyager Therapeutics (VYGR), sold 4,174 shares on 2026-02-24 at a weighted average price of $3.76 per share, generating proceeds of approximately $15,694. The sale was a disposition (S) and was not a discretionary trade.

Key Details

• Transaction date: 2026-02-24
• Price: weighted average $3.76; individual sale prices ranged from $3.61 to $3.86 (per footnote)
• Total proceeds: ~$15,694
• Shares owned after transaction: Not specified in the provided filing
• Footnotes:
  • F1: Sale executed pursuant to a durable automatic sell-to-cover instruction adopted May 12, 2025 to satisfy tax withholding in connection with RSU vesting (vesting occurred Feb 21, 2026). Sales were not discretionary.
  • F2: Reported price is a weighted average; full per-price breakdown is available upon request per the Form 4 footnote.
• Filing: Form 4 was filed on 2026-02-26 (two days after the transaction); this appears to be within the SEC’s 2-business-day reporting window.

Context

• This was a sell-to-cover to satisfy tax withholding after restricted stock units vested, a routine administrative transaction rather than an open-market, discretionary sell. Such transactions are common following RSU vesting and generally reflect tax obligations rather than an expression of the insider’s view on the stock.